投资25亿美元在北京建立全球第六个战略研发中心并达成多项合作、与石药集团签订战略研发合作协议开发新型口服小分子候选药物……今年以来,全球生物制药巨头阿斯利康加码中国动作频频。6月24日,2025年服贸会“高管谈服贸”系列采访活动走进阿斯利康,媒体记者就关心问题与阿斯利康(中国)副总裁、企业事务及市场准入负责人黄彬,阿斯利康(中国)中央政府事务及非政府组织事务执行总监刘芳展开面对面交流,并参观了...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.